Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study
Name:
36442608.pdf
Size:
1.869Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Heumann, P.Aguado-Barrera, M. E.
Avuzzi, B.
Azria, D.
Briers, E.
Bultijnck, R.
Choudhury, Ananya
De Ruysscher, D.
Farcy-Jacquet, M. P.
Fonteyne, V.
Gómez Caamaño, A.
Helmbold, I.
Johnson, K.
Kerns, S. L.
Lambrecht, M.
Lingard, Zoe
Rancati, T.
Rosenstein, B. S.
Sperk, E.
Paul Symonds, R.
Talbot, C.
Valdagni, R.
Vega, A.
Veldeman, L.
Ward, T.
Webb, A.
West, Catharine M L
Chang-Claude, J.
Seibold, P.
Affiliation
German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, GermanyIssue Date
2022
Metadata
Show full item recordAbstract
Introduction: Previous studies showed that healthcare professionals and patients had only moderate to low agreement on their assessment of treatment-related symptoms. We aimed to determine the levels of agreement in a large cohort of prostate cancer patients. Methods: Analyses were made of data from 1,756 prostate cancer patients treated with external beam radiotherapy (RT) and/or brachytherapy in Europe and the USA and recruited into the prospective multicentre observational REQUITE study. Eleven pelvic symptoms at the end of RT were compared after translating patient-reported outcomes (PROs) into CTCAE-based healthcare professional ratings. Gwet's AC2 agreement coefficient and 95% confidence intervals were calculated for each symptom. To compare severity of grading between patients and healthcare professionals, percent agreement and deviations for each symptom were graphically depicted. Stratified and sensitivity analyses were conducted to identify potential influencing factors and to assess heterogeneity and robustness of results. Results: The agreement for the 11 pelvic symptoms varied from very good (AC2 > 0.8: haematuria, rectal bleeding, management of sphincter control) to poor agreement (AC2 ≤ 0.2: proctitis and urinary urgency). Fatigue had a negative impact on the agreement. Patients tended to grade symptoms more severely than healthcare professionals. Information on sexual dysfunction was missing more frequently in healthcare professional assessment than PROs. Conclusion: Agreement was better for observable than subjective symptoms, with patients usually grading symptoms more severely than healthcare professionals. Our findings emphasize that PROs should complement symptom assessment by healthcare professionals and be taken into consideration for clinical decision-making to incorporate the patient perspective.Citation
Heumann P, Aguado-Barrera ME, Avuzzi B, Azria D, Briers E, Bultijnck R, et al. Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 Nov 25;178:109426. PubMed PMID: 36442608. Epub 2022/11/29. eng.Journal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2022.11.015PubMed ID
36442608Additional Links
https://dx.doi.org/10.1016/j.radonc.2022.11.015Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2022.11.015
Scopus Count
Collections
Related articles
- Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.
- Authors: Aguado-Barrera ME, Lopez-Pleguezuelos C, Gómez-Caamaño A, Calvo-Crespo P, Taboada-Valladares B, Azria D, Boisselier P, Briers E, Chan C, Chang-Claude J, Coedo-Costa C, Crujeiras-González A, Cuaron JJ, Defraene G, Elliott RM, Faivre-Finn C, Franceschini M, Fuentes-Rios O, Galego-Carro J, Gutiérrez-Enríquez S, Heumann P, Higginson DS, Johnson K, Lambrecht M, Lang P, Lievens Y, Mollà M, Ramos M, Rancati T, Rattay T, Rimner A, Rosenstein BS, Sangalli C, Seibold P, Sperk E, Stobart H, Symonds P, Talbot CJ, Vandecasteele K, Veldeman L, Ward T, Webb A, Woolf D, de Ruysscher D, West CML, Vega A, REQUITE Consortium
- Issue date: 2025 Jan
- REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
- Authors: Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J, REQUITE consortium
- Issue date: 2019 Sep
- Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
- Authors: Choudhury A, Arthur C, Malik J, Mandall P, Taylor C, Alam N, Tran A, Livsey J, Elliott T, Davidson S, Logue JP, Wylie J
- Issue date: 2014 Oct
- Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.
- Authors: Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, Broughman JR, Reeve BB, Nielsen ME, Usinger DS, Spearman KC, Walden S, Kaleel D, Anderson M, Stürmer T, Godley PA
- Issue date: 2017 Mar 21
- RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
- Authors: Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, Cella D
- Issue date: 1995 Nov 1